Tumour epithelial expression levels of endocannabinoid markers modulate the value of endoglin-positive vascular density as a prognostic marker in prostate cancer

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1831, Issue 10, 2013, Pages 1579-1587

  Fowler, Christopher J ^a   Josefsson, Andreas ^a   Thors, Lina ^a,b   Chung, Sui Chu ^a   Hammarsten, Peter ^a   Wikström, Pernilla ^a   Bergh, Anders ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b SWEDISH DEFENCE RESEARCH AGENCY   (Sweden)

Author keywords

Angiogenesis; Endoglin; Fatty acid amide hydrolase; Prostate cancer; Von Willebrand factor

Indexed keywords

ENDOCANNABINOID; ENDOGLIN; FATTY ACID AMIDASE; TUMOR MARKER; VON WILLEBRAND FACTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL DENSITY; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; EPITHELIUM CELL; EPITHELIUM TUMOR; HUMAN; IMMUNOREACTIVITY; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RAT; TRANSURETHRAL RESECTION; TUMOR CELL LINE; TUMOR GROWTH; VASCULAR TUMOR;

EID: 84885185029     PISSN: 13881981     EISSN: 18792618     Source Type: Journal    
DOI: 10.1016/j.bbalip.2012.12.005     Document Type: Article

References (57)

1. N. Battista, R. Meccariello, G. Cobellis, S. Fasano, M. Di Tommaso, V. Pirazzi, J.C. Konje, R. Pierantoni, M. Maccarrone, The role of endocannabinoids in gonadal function and fertility along the evolutionary axis, Mol. Cell. Endocrinol. 355 (2012) 1-14.
2. G. Kunos, J. Tarn, The case for peripheral CB1 receptor blockade in the treatment of visceral obesity and its cardiometabolic complications, Br. J. Pharmacol. 163 (2011) 1423-1431.
3. T. Biró, B.I. Tóth, G. Haskó, R. Paus, P. Pacher, The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities, Trends Pharmacol. Sci. 30 (2009) 411-420.
4. C.J. Fowler, S.B. Gustafsson, S.C. Chung, E. Persson, S.O.P. Jacobsson, A. Bergh, Targeting the endocannabinoid system for the treatment of cancer - a practical view, Curr. Top. Med. Chem. 10 (2010) 814-827.
5. N. Freimuth, R. Ramer, B. Hinz, Antitumorigenic effects of cannabinoids beyond apoptosis, J. Pharmacol. Exp. Ther. 332 (2010) 336-344.
6. I. Díaz-Laviada, The endocannabinoid system in prostate cancer, Nat Rev. Urol. 8 (2011) 553-561.
7. J. Guindon, A.G. Hohmann, The endocannabinoid system and cancer: therapeutic implication, Br. J. Pharmacol. 163 (2011) 1447-1463.
8. G. Velasco, C. Sánchez, M. Guzmán, Towards the use of cannabinoids as antitumour agents, Nat Rev. Cancer 12 (2012) 436-444.
9. 9- tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism, FEBS Lett. 458 (1999) 400-404. (Pubitemid 29433843)
10. D. Melck, L. De Petrocellis, P. Orlando, T. Bisogno, C. Laezza, M. Bifulco, V. Di Marzo, Suppression of nerve growth factor trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation, Endocrinology 141 (2000) 118-126. (Pubitemid 32260350)
11. M. Mimeault, N. Pommery, N. Wattez, C. Bailly, J.-P. Hénichart, Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production, Prostate 56 (2003) 1-12. (Pubitemid 36613150)
12. K. Nithipatikom, M. Endsley, M. Isbell, J. Falck, Y. Iwamoto, C. Hillard, W. Campbell, 2-Arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion, Cancer Res. 64 (2004) 8826-8830. (Pubitemid 39665485)
13. S. Sarfaraz, F. Afaq, V. Adhami, H. Mukhtar, Cannabinoid receptor as a novel target for the treatment of prostate cancer, Cancer Res. 65 (2005) 1635-1641. (Pubitemid 40478586)
14. S. Sarfaraz, F. Afaq, V. Adhami, A. Malik, H. Mukhtar, Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell arrest, J. Biol. Chem. 281 (2006) 39480-39491. (Pubitemid 46041908)
15. 2, Br. J. Cancer 101 (2009) 940-950.
16. I. Brown, M.G. Cascio, K.W.J. Wahle, R. Smoum, R Mechoulam, RA Ross, R.G. Pertwee, S.D. Heys, Cannabinoid receptor-dependent and -independent antiproliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines, Carcinogenesis 31 (2010) 1584-1591.
17. K. Nithipatikom, M.A. Isbell, M.P. Endsley, J.E. Woodliff, W.B. Campbell, Anti-proliferative effect of a putative endocannabinoid, 2-arachidonylglyceryl ether in prostate carcinoma cells, Prostaglandins Other Lipid Mediat 94 (2011) 34-43.
18. S. Sreevalsan, S. Joseph, I. Jutooru, G. Chadalapaka, S.H. Safe, Induction of apoptosis by cannabinoids in prostate and colon cancer cells is phosphatase dependent, Anticancer. Res. 31 (2011) 3799-3807.
19. D.K. Nomura, D.P. Lombardi, J.W. Chang, S. Niessen, A.M Ward, J.Z. Long, H.H. Hoover, B.F. Cravatt, Monoacylglycerol lipase exerts dual control over endocannabinoid and fatty acid pathways to support prostate cancer, Chem Biol. 18 (2011) 846-856.
20. K. Nithipatikom, M. Endsley, M. Isbell, C. Wheelock, B. Hammock, W. Campbell, A new class of inhibitors of 2-arachidonoylglycerol hydrolysis and invasion of prostate cancer cells, Biochem. Biophys. Res. Commun. 332 (2005) 1028-1033. (Pubitemid 40798189)
21. M. Endsley, R. Thill, I. Choudhry, C. Williams, A. Kajdacsy-Balla, W. Campbell, K. Nithipatikom, Expression and function of fatty acid amide hydrolase in prostate cancer, Int. J. Cancer 123 (2008) 1318-1326.
22. J. Wang, L-Y. Zhao, T. Uyama, K. Tsuboi, X.-X. Wu, Y. Kakehi, N. Ueda, Expression and secretion of N-acylethanolamine-hydrolysing acid amidase in human prostate cancer cells, J. Biochem. 144 (2008) 685-690.
23. L Thors, A. Bergh, E. Persson, P. Hammarsten, P. Stattin, L Egevad, T. Granfors, C.J. Fowler, Fatty acid amide hydrolase in prostate cancer: association with disease severity and outcome, CB1 receptor expression and regulation by IL-4, PLoS One 5 (2010) e12275.
24. D. Gleason, G. Mellinger, Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging, J. Urol. 111 (1974) 58-64.
25. A. Josefsson, P. Wikström, L Egevad, T. Granfors, L Karlberg, P. Stattin, A. Bergh, Low endoglin vascular density and Ki67 index in Gleason score 6 tumours may identify prostate cancer patients suitable for surveillance, Scand. J. Urol. Nephrol. 46 (2012) 247-257.
26. S.C. Chung, P. Hammarsten, A. Josefsson, P. Stattin, T. Granfors, L. Egevad, G. Mancini, B. Lutz, A. Bergh, C.J. Fowler, A high cannabinoid CB1 receptor immuno-reactivity is associated with disease severity and outcome in prostate cancer, Eur. J. Cancer 45 (2009) 174-182.
27. G. Portella, C. Laezza, P. Laccetti, L. De Petrocellis, V. Di Marzo, M. Bifulco, Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis, FASEBJ. 17 (2003) 1771-1773.
28. C. Blázquez, M. Casanova, A. Palanas, T. Gómez del Pulgar, C. Villanueva, M. Fernández-Aceñero, J. Aragonés, J. Huffman, J. Jorcano, M. Guzmán, Inhibition of tumor angiogenesis by cannabinoids, FASEBJ. 17 (2003) 529-531.
29. M. Casanova, C Blázquez, J. Martínez-Palacio, C. Villanueva, M. Fernández-Aceñero, J. Huffman, J. Jorcano, M. Guzmán, Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors, J. Clin. Invest 111 (2003) 43-50. (Pubitemid 36134847)
30. S. Sarfaraz, F. Afaq, V. Adhami, A. Malik, I. Siddiqui, H. Mukhtar, Cannabinoid receptors agonist WIN-55,212-2 inhibits angiogenesis, metastasis and tumor growth of androgen-sensitive prostate cancer cell CWR22Rv1 xenograft in athymic nude mice, in: Proceedings of the 98th Annual Meeting of the American Association for Cancer Research; 2007 Apr 14-18; Los Angeles, CA, USA, AACR, Philadelphia (PA), 2007 (Abstract nr 2195. Available online at http://www.aacrmeetingabstracts.org/).
31. L. Egevad, T. Granfors, L. Karlberg, A. Bergh, P. Stattin, Prognostic value of the Gleason score in prostate cancer, BJU Int 89 (2002) 538-542. (Pubitemid 34948295)
32. P. Hammarsten, S. Halin, P. Wikström, R. Henriksson, S. Häggström Rudolfsson, A. Bergh, Inhibitory effects of castration in an orthotopic model of androgen-independent prostate cancer can be mimicked and enhanced by angiogenesis inhibition, Clin. Cancer Res. 12 (2006) 7431-7436. (Pubitemid 46095418)
33. S. Halin, P. Hammarsten, P. Wikström, A. Bergh, Androgen-insensitive prostate cancer cells transiently respond to castration treatment when growing in an androgen-dependent prostate environment, Prostate 67 (2007) 370-377. (Pubitemid 46341077)
34. T. Harkany, W. Härtig, P. Berghuis, M. Dobszay, Y. Zilberter, R. Edwards, K. Mackie, P. Ernfors, Complementary distribution of type 1 cannabinoid receptors and vesicular glutamate transporter 3 in basal forebrain suggests input-specific retrograde signalling by cholinergic neurons, Eur. J. Neurosci. 18 (2003) 1979-1992. (Pubitemid 37372380)
35. L. Thors, J. Eriksson, C.J. Fowler, Inhibition of the cellular uptake of anandamideby genistein and its analogue daidzein in cells with different levels of fatty acid amide hydrolase-driven uptake, Br. J. Pharmacol. 152 (2007) 744-750. (Pubitemid 350034971)
36. M.H. Zweig, G. Campbell, Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine, Clin. Chem. 39 (1993) 561-577. (Pubitemid 23118304)
37. D.R. Cox, Regression models and life-tables, J. Roy. Stat Soc. B 34 (1972) 187-220.
38. L.M. Sherwood, E.E. Parris, Tumor angiogenesis: therapeutic implications, N. Engl. J. Med. 285 (1971) 1182-1186.
39. R.J. Young, M.W.R. Reed, Anti-angiogenic therapy: concept to clinic, Microcirculation 19 (2012) 115-125.
40. E.S. Antonarakis, M.A. Carducci, Targeting angiogenesis for the treatment of prostate cancer, Expert Opin. Ther. Targets 16 (2012) 365-376.
41. P. Wikström, I. Franck Lissbrant, P. Stattin, L. Egevad, A. Bergh, Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer, Prostate 51 (2002) 268-275. (Pubitemid 34556377)
42. B.V. Offersen, M. Borre, F. Brandt Sørensen, J. Overgaard, Comparison of methods of microvascular staining and quantification in prostate carcinoma: relevance to prognosis, APMIS 110 (2002) 177-185. (Pubitemid 34327157)
43. M.A. Rubin, M. Buyyounouski, E. Bagiella, S. Sharir, A. Neugut, M. Benson, A. de la Taille, A.E. Katz, C.A. Olsson, R.D. Ennis, Microvessel density in prostate cancer: lack of correlation with tumor grade, pathologic stage, and clinical outcome, Urology 53 (1999) 542-547. (Pubitemid 29136199)
44. A. Josefsson, P. Wikström, T. Granfors, L. Egevad, L. Karlberg, P. Stattin, A. Bergh, Tumor size, vascular density and proliferation as prognostic markers in GS6 and GS7 prostate tumors in patients with long follow-up and non-curative treatment, Eur. Urol. 48 (2005) 577-583. (Pubitemid 41278582)
45. Y.M. El-Gohary, J.F. Silverman, P.R. Olson, Y.L. Liu, J.K. Cohen, R. Miller, R.S. Saad, Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma, Am. J. Clin. Pathol. 127 (2007) 572-579. (Pubitemid 46587470)
46. R.S. Svatek, J.A. Karam, C.G. Roehrborn, P.I. Karakiewicz, K.M. Slawin, S.F. Shariat, Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy, Clin. Cancer Res. 14 (2008) 3362-3366.
47. K. Fujita, C.M. Ewing, D.Y. Chan, L.A. Mangold, A.W. Partin, W.B. Isaacs, C.P. Pavlovich, Endoglin (CD105) as a urinary and serum marker of prostate cancer, Int. J. Cancer 124 (2009) 664-669.
48. F. Botelho, F. Pina, N. Lunet, VEGF and prostatic cancer: a systematic review, Eur. J. Cancer Prev. 19 (2010) 385-392.
49. S. Pisanti, C. Borselli, O. Oliviero, C. Laezza, P. Gazzerro, M. Bifulco, Antiangiogenic activity of the endocannabinoid anandamide: correlation to its tumor-suppressor efficacy, J. Cell. Physiol. 211 (2007) 495-503. (Pubitemid 46580103)
50. 2 receptors determines their efficacy at inducing apoptosis in astrocytomas, PLoS One 5 (2010) e8702.
51. 2 receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction, Cell. Signal. 15 (2003) 851-859. (Pubitemid 36776659)
52. N. Ueda, K. Tsuboi, T. Uyama, T. Ohnishi, Biosynthesis and degradation of the endocannabinoid 2-arachidonoylglycerol, Biofactors 37 (2011) 1-7.
53. M. Bektas, S. Payne, H. Liu, S. Goparaju, S. Milstien, S. Spiegel, A novel acylglycerol kinase that produces lysophosphatidic acid modulates cross talk with EGFR in prostate cancer cells, J. Cell Biol. 169 (2005) 801-811. (Pubitemid 41002885)
54. M. Endsley, N. Aggarwal, M. Isbell, C. Wheelock, B. Hammock, J. Falck, W. Campbell, K. Nithipatikom, Diverse roles of 2-arachidonoylglycerol in invasion of prostate carcinoma cells: location, hydrolysis and 12-lipoxygenase metabolism, Int. J. Cancer 121 (2007) 984-991. (Pubitemid 47101633)
55. G. Czifra, A. Varga, K. Nyeste, R. Marincsák, B. Tóth, I. Kovács, L. Kovács, T. Bíró, Increased expressions of cannabinoid receptor-1 and transient receptor potential vanilloid-1 in human prostate carcinoma, J. Cancer Res. Clin. Oncol. 135 (2009) 507-514.
56. M. Sánchez, A. Sánchez, B. Collado, S. Malagerie-Cazenave, N. Olea, M. Carmena, J. Prieto, I. Díaz-Laviada, Expression of the transient receptor potential vanilloid 1 (TRPV1) in LNCaP and PC-3 prostate cancer cells and in human prostate tissue, Eur. J. Pharmacol. 515 (2005) 20-27. (Pubitemid 40779263)
57. S. Shao, N. Feng, Y. Wang, Y. Mi, L. Hua, Systematic review and meta-analysis of COX-2 expression and polymorphisms in prostate cancer, Mol. Biol. Rep. 39 (2012) 10997-11004.